Madrigal Pharmaceuticals (MDGL) to Release Quarterly Earnings on Thursday

Madrigal Pharmaceuticals (NASDAQ:MDGL) is expected to release its Q4 2025 results before the market opens on Thursday, February 19th. Analysts expect the company to announce earnings of ($0.01) per share and revenue of $310.3580 million for the quarter. Interested persons can find conference call details on the company’s upcoming Q4 2025 earning report page for the latest details on the call scheduled for Thursday, February 19, 2026 at 8:00 AM ET.

Madrigal Pharmaceuticals Trading Up 4.9%

NASDAQ MDGL opened at $487.32 on Wednesday. The firm has a market cap of $11.07 billion, a PE ratio of -37.46, a price-to-earnings-growth ratio of 6.60 and a beta of -1.01. Madrigal Pharmaceuticals has a 1-year low of $265.00 and a 1-year high of $615.00. The stock has a 50-day moving average of $528.25 and a 200-day moving average of $480.69. The company has a current ratio of 3.44, a quick ratio of 3.26 and a debt-to-equity ratio of 0.54.

Insider Buying and Selling

In other Madrigal Pharmaceuticals news, insider Carole Huntsman sold 1,958 shares of the firm’s stock in a transaction dated Friday, November 21st. The shares were sold at an average price of $553.11, for a total value of $1,082,989.38. Following the completion of the sale, the insider directly owned 10,032 shares in the company, valued at $5,548,799.52. This trade represents a 16.33% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at this link. Also, Director Paul A. Friedman sold 24,800 shares of the stock in a transaction that occurred on Wednesday, December 10th. The stock was sold at an average price of $552.18, for a total value of $13,694,064.00. Following the completion of the transaction, the director directly owned 187,164 shares of the company’s stock, valued at $103,348,217.52. This represents a 11.70% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold 101,495 shares of company stock valued at $54,568,691 over the last quarter. 21.50% of the stock is currently owned by insiders.

Institutional Trading of Madrigal Pharmaceuticals

A number of hedge funds have recently modified their holdings of the business. Quarry LP bought a new position in shares of Madrigal Pharmaceuticals in the 3rd quarter worth about $39,000. Kemnay Advisory Services Inc. purchased a new stake in Madrigal Pharmaceuticals in the fourth quarter worth about $39,000. Johnson Financial Group Inc. bought a new position in shares of Madrigal Pharmaceuticals during the third quarter valued at approximately $50,000. Kestra Investment Management LLC purchased a new position in shares of Madrigal Pharmaceuticals during the second quarter valued at approximately $85,000. Finally, Smartleaf Asset Management LLC boosted its position in shares of Madrigal Pharmaceuticals by 50.8% in the 4th quarter. Smartleaf Asset Management LLC now owns 187 shares of the biopharmaceutical company’s stock worth $109,000 after purchasing an additional 63 shares in the last quarter. Institutional investors own 98.50% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of analysts have recently weighed in on MDGL shares. The Goldman Sachs Group reissued a “buy” rating and set a $571.00 price objective on shares of Madrigal Pharmaceuticals in a research note on Wednesday, January 14th. Weiss Ratings reissued a “sell (d-)” rating on shares of Madrigal Pharmaceuticals in a research report on Thursday, January 22nd. Zacks Research cut shares of Madrigal Pharmaceuticals from a “hold” rating to a “strong sell” rating in a research report on Monday, January 12th. Citigroup reaffirmed an “outperform” rating on shares of Madrigal Pharmaceuticals in a research note on Tuesday, January 20th. Finally, Truist Financial raised their target price on Madrigal Pharmaceuticals from $580.00 to $640.00 and gave the stock a “buy” rating in a research note on Wednesday, November 19th. One equities research analyst has rated the stock with a Strong Buy rating, twelve have issued a Buy rating, two have given a Hold rating and two have assigned a Sell rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $663.86.

About Madrigal Pharmaceuticals

Madrigal Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the development of innovative therapies for cardiovascular, metabolic and liver diseases. The company’s pipeline centers on novel, liver-directed agents designed to address significant unmet medical needs, with an emphasis on nonalcoholic steatohepatitis (NASH) and related metabolic disorders.

The lead product candidate, resmetirom (MGL-3196), is an orally administered, selective thyroid hormone receptor-β agonist in Phase 3 development for the treatment of NASH.